{"entity":{"id":"acns1422","kind":"trial","name":"ACNS1422","aka":["COG ACNS1422"],"tldr":"ACNS1422 tests whether children with the WNT type of medulloblastoma, who almost always survive, can be given less radiotherapy to the brain and spine and less chemotherapy without more relapses; it has finished enrolling and the results are awaited.","summary":"ACNS1422 is a single-arm Children's Oncology Group phase 2 study of reduced therapy for children with average-risk WNT-activated medulloblastoma, a subgroup with survival above 90 percent on standard treatment. Craniospinal irradiation is reduced from 23.4 Gy to 18 Gy with a reduced boost volume, and maintenance chemotherapy is shortened. The primary endpoint is progression-free survival.\n\nThe registry gives an estimated enrolment of 45 with a primary completion date of March 2028 and no results. The corpus's WNT medulloblastoma page cites it with the St. Jude SJMB12 study (15 Gy) as the trials that define reduced-dose radiotherapy for this subgroup.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02724579","url":"https://clinicaltrials.gov/study/NCT02724579"}],"tags":["soc-trials"],"related":[],"cancers":["medulloblastoma-wnt","medulloblastoma","brain-tumours","childhood-cancers"],"sections":[],"technologies":["imrt-igrt","cytotoxic-chemotherapy"],"targets":[],"drugs":["cisplatin","cyclophosphamide","lomustine","vincristine"],"companies":[],"institutions":["childrens-oncology-group"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02724579","phase":"2","setting":"Newly diagnosed average-risk WNT-driven medulloblastoma in children aged 3 to 21: reduced craniospinal irradiation of 18 Gy with a reduced tumour-bed boost and reduced maintenance chemotherapy (cisplatin, cyclophosphamide, lomustine, vincristine)","sponsor":"Children's Oncology Group","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/acns1422/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"institution":[{"id":"childrens-oncology-group","kind":"institution","name":"Children's Oncology Group (COG)","route":"/institutions/childrens-oncology-group/"}]}}